Indexado en

Licencia y uso

Citaciones

Cited 2 times in

Cited 2 times in

Altmetrics

Grant support

A.G.Q., A.I.M. and D.F. acknowledge Spanish MINECO under grant PID2019-106220RB100 and PID2022-137373OB-I00. The authors acknowledge the Multifunctional Metallodrugs in Diagnosis and Therapy Network (MICIU, RED2018-102471-T) as well as T.H. thanks the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No. 897678.

Análisis de autorías institucional

Compartir

Proving the antimicrobial therapeutic activity on a new Copper-Thiosemicarbazone Complex

Publicado en:MOLECULAR PHARMACEUTICS. 21 (4): 1987-1997 - 2024-03-20 21(4), DOI: 10.1021/acs.molpharmaceut.3c01235

Autores: Fabra, David; Amariei, Georgiana; Ruiz-Camino, Daniel; Matesanz, Ana I; Rosal, Roberto; Quiroga, Adoracion G; Horcajada, Patricia; Hidalgo, Tania

Afiliaciones

Resumen

The misuse and overdose of antimicrobial medicines are fostering the emergence of novel drug-resistant pathogens, providing negative repercussions not only on the global healthcare system due to the rise of long-term or chronic patients and inefficient therapies but also on the world trade, productivity, and, in short, to the global economic growth. In view of these scenarios, novel action plans to constrain this antibacterial resistance are needed. Thus, given the proven antiproliferative tumoral and microbial features of thiosemicarbazone (TSCN) ligands, we have here synthesized a novel effective antibacterial copper-thiosemicarbazone complex, demonstrating both its solubility profile and complex stability under physiological conditions, along with their safety and antibacterial activity in contact with human cellular nature and two most predominant bacterial strains, respectively. A significant growth inhibition (17% after 20 h) is evidenced over time, paving the way toward an effective antibacterial therapy based on these copper-TSCN complexes.

Palabras clave